RT Journal Article
SR Electronic
T1 Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: a cross sectional analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.22.22276763
DO 10.1101/2022.06.22.22276763
A1 Prasad, Vinay
A1 Olivier, Timothée
A1 Chen, Emerson Y
A1 Haslam, Alyson
YR 2022
UL http://medrxiv.org/content/early/2022/06/22/2022.06.22.22276763.abstract
AB Background Financial costs from cancer treatment are increasingly recognized, but what has historically been underrecognized is the time cost of therapy. We sought to estimate the time burden of anti-cancer drugs approved based on comparisons to best supportive care (BCS), with the assumption that without this drug, a patient could have been treated with observation, home palliative care or hospice services, with minimal time seeking medical care.Methods We searched all FDA approvals (2009 - March 2022) for randomized trials that used BCS as a treatment option for an anti-tumor drug in the metastatic setting and abstracted data on treatment related activities. We then estimated time spent on these activities using previously calculated times.Results Of the 13 drugs tested against BSC, nine studies demonstrated an improvement in median OS (median 2.1 months). The median monthly time spent for patients in the intervention arm of BSC trials was 15.8 hours.Conclusion Time is a valuable resource for people who have cancer, but especially for patients who may have few to no remaining treatment options, and yet, we found that patients can spend up to 16 hours in anti-cancer drug related activities per month.Competing Interest StatementVinay Prasad's Disclosures; (research funding) Arnold Ventures; (royalties) Johns Hopkins Press, Medscape (honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, professional societies, Youtube, and Substack (consulting); UnitedHealthcare; (speaking fees) Evicore; (other) Plenary Session podcast has Patreon backers. All other authors have no financial nor non-financial conflicts of interest to report.Funding StatementThis project was funded by Arnold VenturesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required because we used publicly available dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll data generated or analyzed during this study are included in the manuscript and supporting file.